

Anas Younes

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2395043/publications.pdf>

Version: 2024-02-01

183
papers

15,345
citations

22153

59
h-index

18130

120
g-index

185
all docs

185
docs citations

185
times ranked

15639
citing authors

#	ARTICLE	IF	CITATIONS
1	Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 2183-2189.	1.6	1,332
2	Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 4-23.	2.8	1,267
3	Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas. <i>New England Journal of Medicine</i> , 2010, 363, 1812-1821.	27.0	1,266
4	Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1283-1294.	10.7	818
5	Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2018, 378, 331-344.	27.0	564
6	Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1428-1439.	1.6	551
7	Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1285-1295.	1.6	388
8	Brentuximab Vedotin (SGN-35). <i>Clinical Cancer Research</i> , 2011, 17, 6428-6436.	7.0	333
9	Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 942-950.	1.6	273
10	Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 2197-2203.	1.6	251
11	Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study. <i>Lancet Oncology</i> , The, 2013, 14, 1348-1356.	10.7	251
12	Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naïve patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. <i>Lancet Oncology</i> , The, 2014, 15, 1019-1026.	10.7	246
13	Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting. <i>Blood</i> , 2016, 127, 3004-3014.	1.4	244
14	A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. <i>British Journal of Haematology</i> , 2009, 146, 171-179.	2.5	230
15	Novel immunotherapies in lymphoid malignancies. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 25-40.	27.6	224
16	Antibiotic Treatment of Gastric Lymphoma of Mucosa-Associated Lymphoid Tissue: An Uncontrolled Trial. <i>Annals of Internal Medicine</i> , 1999, 131, 88.	3.9	206
17	Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. <i>Blood</i> , 2015, 125, 1236-1243.	1.4	199
18	MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. <i>Blood</i> , 2003, 102, 1019-1027.	1.4	190

#	ARTICLE	IF	CITATIONS
19	A phase 1 multidose study of SCN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies. <i>Blood</i> , 2008, 111, 1848-1854.	1.4	189
20	Temsirolimus Has Activity in Non-â€Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium. <i>Journal of Clinical Oncology</i> , 2010, 28, 4740-4746.	1.6	181
21	Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2011, 12, 1222-1228.	10.7	168
22	Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 2776-2782.	1.6	162
23	A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. <i>Cancer</i> , 2003, 98, 310-314.	4.1	160
24	Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. <i>Blood</i> , 2008, 112, 1424-1433.	1.4	152
25	Brentuximab vedotin. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 19-20.	46.4	151
26	Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial. <i>Lancet Oncology</i> , The, 2016, 17, 622-631.	10.7	149
27	Follicular lymphoma. <i>Nature Reviews Disease Primers</i> , 2019, 5, 83.	30.5	148
28	Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study. <i>Lancet Haematology</i> , the, 2019, 6, e67-e78.	4.6	146
29	Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma assessment of activity and toxicity. <i>Cancer</i> , 1990, 66, 2470-2475.	4.1	136
30	Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies. <i>British Journal of Haematology</i> , 1997, 99, 618-624.	2.5	120
31	Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. <i>Leukemia and Lymphoma</i> , 2013, 54, 2531-2533.	1.3	120
32	Functional expression of receptor activator of nuclear factor Î² in Hodgkin disease cell lines. <i>Blood</i> , 2001, 98, 2784-2790.	1.4	117
33	Emerging Applications of the Tumor Necrosis Factor Family of Ligands and Receptors in Cancer Therapy. <i>Journal of Clinical Oncology</i> , 2003, 21, 3526-3534.	1.6	104
34	Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma. <i>Clinical Cancer Research</i> , 2013, 19, 6882-6890.	7.0	103
35	Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. <i>Cancer Discovery</i> , 2020, 10, 440-459.	9.4	103
36	HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma. <i>Blood</i> , 2011, 117, 2910-2917.	1.4	99

#	ARTICLE	IF	CITATIONS
37	Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor. Expert Opinion on Investigational Drugs, 2011, 20, 823-829.	4.1	98
38	CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial. Haematologica, 2017, 102, 1923-1930.	3.5	98
39	The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints. Haematologica, 2016, 101, 794-802.	3.5	94
40	Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. British Journal of Haematology, 2005, 132, 051220022257008.	2.5	87
41	A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma. British Journal of Haematology, 2017, 178, 434-441.	2.5	86
42	Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Blood, 2020, 135, 735-742.	1.4	86
43	Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Lancet Haematology, the, 2021, 8, e410-e421.	4.6	83
44	Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma. British Journal of Haematology, 2015, 171, 463-470.	2.5	81
45	Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer Journal, 2020, 10, 74.	6.2	81
46	Emerging epigenetic-modulating therapies in lymphoma. Nature Reviews Clinical Oncology, 2019, 16, 494-507.	27.6	80
47	The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines. Blood, 2012, 119, 4017-4025.	1.4	79
48	Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. Blood Cancer Journal, 2019, 9, 50.	6.2	75
49	Beyond chemotherapy: new agents for targeted treatment of lymphoma. Nature Reviews Clinical Oncology, 2011, 8, 85-96.	27.6	73
50	Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4. Clinical Cancer Research, 2011, 17, 7058-7066.	7.0	72
51	Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood, 2012, 119, 4123-4128.	1.4	70
52	Precision therapy for lymphoma—current state and future directions. Nature Reviews Clinical Oncology, 2014, 11, 585-596.	27.6	69
53	FDG PET/CT imaging as a biomarker in lymphoma. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 623-633.	6.4	68
54	European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. Cancer, 2002, 94, 1731-1738.	4.1	67

#	ARTICLE	IF	CITATIONS
55	Detection of circulating tumour <scp>DNA</scp> in patients with aggressive Bâ€cell nonâ€Hodgkin lymphoma. British Journal of Haematology, 2013, 163, 123-126.	2.5	67
56	CD30 ligand is expressed on resting normal and malignant human B lymphocytes. British Journal of Haematology, 1996, 93, 569-571.	2.5	66
57	Encouraging activity for R-CHOP in advanced stage nodular lymphocyteâ€predominant Hodgkin lymphoma. Blood, 2017, 130, 472-477.	1.4	65
58	Radiotherapy Alone for Lymphocyte-Predominant Hodgkin??s Disease. Cancer Journal (Sudbury, Mass), 2002, 8, 377-383.	2.0	64
59	Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. Blood Advances, 2020, 4, 4669-4678.	5.2	64
60	CD30-targeted antibody therapy. Current Opinion in Oncology, 2011, 23, 587-593.	2.4	61
61	Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood, 2016, 128, 1458-1464.	1.4	61
62	Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma. Current Treatment Options in Oncology, 2016, 17, 31.	3.0	57
63	The landscape of new drugs in lymphoma. Nature Reviews Clinical Oncology, 2017, 14, 335-346.	27.6	56
64	ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma. Haematologica, 2016, 101, 968-975.	3.5	52
65	BET Inhibitor CPI-0610 Is Well Tolerated and Induces Responses in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma: Preliminary Analysis of an Ongoing Phase 1 Study. Blood, 2015, 126, 1491-1491.	1.4	52
66	The classâ€HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6â€independent mechanism. British Journal of Haematology, 2010, 151, 387-396.	2.5	51
67	OncoTree: A Cancer Classification System for Precision Oncology. JCO Clinical Cancer Informatics, 2021, 5, 221-230.	2.1	51
68	From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy. Expert Review of Anticancer Therapy, 2006, 6, 131-140.	2.4	50
69	The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma. British Journal of Haematology, 2014, 165, 112-116.	2.5	50
70	A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL. Blood, 2018, 131, 1805-1808.	1.4	49
71	Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy. Annals of Hematology, 2014, 93, 1263-1277.	1.8	48
72	Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacy. Leukemia and Lymphoma, 2014, 55, 2328-2334.	1.3	48

#	ARTICLE	IF	CITATIONS
73	Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma. <i>Oncotarget</i> , 2017, 8, 14017-14028.	1.8	48
74	Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. <i>Blood</i> , 2019, 133, 2121-2129.	1.4	46
75	The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. <i>Experimental Hematology</i> , 2011, 39, 1007-1017.e1.	0.4	43
76	Brentuximab Vedotin in Transplant-Naïve Patients with Relapsed or Refractory Hodgkin Lymphoma: Analysis of Two Phase I Studies. <i>Oncologist</i> , 2012, 17, 1073-1080.	3.7	42
77	Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma. <i>Haematologica</i> , 2017, 102, 2104-2112.	3.5	41
78	NOXA genetic amplification or pharmacologic induction primes lymphoma cells to BCL2 inhibitor-induced cell death. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 12034-12039.	7.1	41
79	Paradigms for Precision Medicine in Epithelial Cancer Therapy. <i>Cancer Cell</i> , 2019, 36, 559-573.e7.	16.8	40
80	MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2013, 162, 336-347.	2.5	39
81	Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era. <i>Blood</i> , 2021, 137, 39-48.	1.4	38
82	Ibrutinib in PCNSL: The Curious Cases of Clinical Responses and Aspergillosis. <i>Cancer Cell</i> , 2017, 31, 731-733.	16.8	37
83	Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma. <i>Blood</i> , 2017, 130, 1375-1377.	1.4	37
84	Characterization of a c-Rel Inhibitor That Mediates Anticancer Properties in Hematologic Malignancies by Blocking NF- κ B-Controlled Oxidative Stress Responses. <i>Cancer Research</i> , 2016, 76, 377-389.	0.9	36
85	Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse. <i>Blood Cancer Journal</i> , 2021, 11, 113.	6.2	35
86	Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 1110-1110.	1.4	35
87	Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial. <i>British Journal of Haematology</i> , 1997, 96, 328-332.	2.5	34
88	Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2257-2265.	1.6	32
89	BET Inhibition-Induced GSK3 β Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors. <i>Cell Reports</i> , 2018, 24, 2155-2166.	6.4	31
90	Lymphomagenesis in Hodgkin lymphoma. <i>Seminars in Cancer Biology</i> , 2015, 34, 14-21.	9.6	29

#	ARTICLE	IF	CITATIONS
91	Novel agents in the treatment of Hodgkin lymphoma: Biological basis and clinical results. Seminars in Hematology, 2016, 53, 186-189.	3.4	26
92	Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. Clinical Cancer Research, 2019, 25, 1718-1726.	7.0	26
93	From drug discovery to biomarker-driven clinical trials in lymphoma. Nature Reviews Clinical Oncology, 2012, 9, 643-653.	27.6	25
94	Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin: Seeing the Forest and the Trees. Journal of Clinical Oncology, 2015, 33, 2835-2836.	1.6	25
95	Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. Blood Cancer Journal, 2018, 8, 60.	6.2	25
96	Novel Targeted Therapies in Diffuse Large B-Cell Lymphoma. Seminars in Hematology, 2015, 52, 126-137.	3.4	24
97	Outcomes of Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Patients Treated with R-CHOP.. Blood, 2010, 116, 2812-2812.	1.4	24
98	Reed-Sternberg Cells and the TNF Family of Receptors/Ligands. Leukemia and Lymphoma, 1997, 27, 195-204.	1.3	23
99	Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma. Cancer Journal (Sudbury, Mass), 2016, 22, 23-26.	2.0	23
100	Polysomy of chromosome 12 in 60 patients with non-hodgkin's lymphoma assessed by fluorescence in situ hybridization: Differences between follicular and diffuse large cell lymphoma. Genes Chromosomes and Cancer, 1994, 9, 161-167.	2.8	22
101	Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin,) Tj ETQq1 1 0.784314 rgBT /Over 863-870.	1.3	22
102	Positron-emission tomographyâ€‘based staging reduces the prognostic impact of early disease progression in patients with follicular lymphoma. European Journal of Cancer, 2020, 126, 78-90.	2.8	21
103	A Phase Ib/IIa Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory T-Cell Lymphomas. Blood, 2016, 128, 2991-2991.	1.4	21
104	Rising Serum Lactate Dehydrogenase Often Caused by Granulocyte-or Granulocyte-Macrophage Colony Stimulating Factor and not Tumor Progression in Patients with Lymphoma or Myeloma. Leukemia and Lymphoma, 1995, 17, 473-477.	1.3	20
105	Brentuximab vedotin in systemic T-cell lymphoma. Expert Opinion on Biological Therapy, 2012, 12, 623-632.	3.1	20
106	Role of CD30 Targeting in Malignant Lymphoma. Current Treatment Options in Oncology, 2014, 15, 210-225.	3.0	19
107	Precision medicine in diffuse large B-cell lymphoma: hitting the target. Haematologica, 2015, 100, 989-93.	3.5	19
108	Risk Classification for Large Cell Lymphoma using Lactate Dehydrogenase, Beta-2 Microglobulin, and Thymidine Kinase. Leukemia and Lymphoma, 1995, 18, 87-92.	1.3	18

#	ARTICLE	IF	CITATIONS
109	Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase- \hat{I} , \hat{I}^3 , in patients with relapsed/refractory lymphoma.. Journal of Clinical Oncology, 2013, 31, 8518-8518.	1.6	18
110	The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma. Clinical Cancer Research, 2017, 23, 4119-4126.	7.0	17
111	Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma. Haematologica, 2019, 104, e163-e166.	3.5	17
112	Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition. Blood, 2021, 137, 2057-2069.	1.4	17
113	Phase 1 Study of CB-839, a First-in-Class, Glutaminase Inhibitor in Patients with Multiple Myeloma and Lymphoma. Blood, 2015, 126, 3059-3059.	1.4	17
114	Prognostic significance of serum B-lymphocyte stimulator level in Hodgkin's lymphoma. Haematologica, 2007, 92, 269-270.	3.5	16
115	From empiric to mechanism-based therapy for peripheral T cell lymphoma. International Journal of Hematology, 2014, 99, 249-262.	1.6	16
116	Novel therapeutic agents for relapsed classical Hodgkin lymphoma. British Journal of Haematology, 2019, 184, 105-112.	2.5	16
117	Brentuximab Vedotin for the Treatment of Patients with Hodgkin Lymphoma. Hematology/Oncology Clinics of North America, 2014, 28, 27-32.	2.2	15
118	Immune Checkpoint Inhibition in Hodgkin Lymphoma. HemaSphere, 2018, 2, e20.	2.7	15
119	A Phase Ib/Ila Trial of the Combination of Romidepsin, Lenalidomide and Carfilzomib in Patients with Relapsed/Refractory Lymphoma Shows Complete Responses in Relapsed and Refractory B- and T-Cell Lymphomas. Blood, 2017, 130, 821-821.	1.4	15
120	Clinical Trials in the Genomic Era. Journal of Clinical Oncology, 2017, 35, 1011-1017.	1.6	14
121	Emerging drugs for diffuse large B-cell lymphoma. Expert Review of Anticancer Therapy, 2015, 15, 439-451.	2.4	13
122	Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy. Leukemia and Lymphoma, 2020, 61, 2931-2938.	1.3	13
123	Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation. Translational Oncology, 2021, 14, 100977.	3.7	13
124	Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring. Clinical Cancer Research, 2022, 28, 45-56.	7.0	13
125	Phase I Study of Fludarabine and Paclitaxel for the Treatment of Low-Grade Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 1997, 26, 77-82.	1.3	12
126	Soluble CD95 in the Serum of Patients with Low and Intermediate Grade Malignant Lymphomas: Absence of Prognostic Correlations. Leukemia and Lymphoma, 1997, 27, 517-521.	1.3	11

#	ARTICLE	IF	CITATIONS
127	A phase 1 dose-escalation study of XmAb [®] 2513 in patients with relapsed or refractory Hodgkin lymphoma. British Journal of Haematology, 2015, 168, 902-904.	2.5	11
128	ABVD plus rituximab <i>versus</i> ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study. Haematologica, 2019, 104, e65-e67.	3.5	11
129	FDG-PET Adapted Sequential Therapy With Brentuximab Vedotin and Augmented ICE Followed By Autologous Stem Cell Transplant For Relapsed and Refractory Hodgkin Lymphoma. Blood, 2013, 122, 2099-2099.	1.4	11
130	Optimising the lymphoma response criteria in the era of targeted therapy. Lancet Oncology, The, 2011, 12, 616-617.	10.7	10
131	An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma or Follicular Lymphoma. Blood, 2014, 124, 1718-1718.	1.4	10
132	Promising Novel Agents for Aggressive B-Cell Lymphoma. Hematology/Oncology Clinics of North America, 2016, 30, 1229-1237.	2.2	9
133	Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of CNS Relapse Treated in the Rituximab Era. Blood, 2019, 134, 1619-1619.	1.4	9
134	Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma. Blood, 2012, 120, 798-798.	1.4	9
135	Five-Year Survival Data Demonstrating Durable Responses from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma. Blood, 2015, 126, 2736-2736.	1.4	8
136	XIV. The rationale for combining targeted and biological anti-lymphoma drugs. Hematological Oncology, 2013, 31, 81-83.	1.7	7
137	Clinical Development of MGCD0103, An Isotype-Selective HDAC Inhibitor: Pericarditis/Pericardial Effusion in the Context of Overall Safety and Efficacy.. Blood, 2009, 114, 4756-4756.	1.4	7
138	ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors. Cell Reports Medicine, 2021, 2, 100350.	6.5	6
139	A First-In-Man Phase 1 Study Of CUDC-907, a First-In-Class Chemically-Designed Dual Inhibitor Of PI3K and HDAC In Patients With Refractory Or Relapsed Lymphoma and Multiple Myeloma. Blood, 2013, 122, 4363-4363.	1.4	5
140	An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL) and Follicular Lymphoma (FL). Blood, 2015, 126, 1493-1493.	1.4	5
141	Chromosome 9p24.1/PD-L1/PD-L2 Alterations and PD-L1 Expression and Treatment Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Nivolumab (PD-1 Blockade). Blood, 2016, 128, 2923-2923.	1.4	5
142	Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study. Cancer Treatment and Research Communications, 2020, 25, 100235.	1.7	4
143	Benchmark of Progression Free Survival for Multiple Lines of Therapy in Follicular Lymphoma Treated in the Rituximab Era. Blood, 2016, 128, 2955-2955.	1.4	4
144	A phase II study of single agent mocetinostat, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in patients with diffuse large cell B-cell (DLBCL) and follicular (FL) lymphomas.. Journal of Clinical Oncology, 2013, 31, 8535-8535.	1.6	4

#	ARTICLE	IF	CITATIONS
145	Lymphomas and microenvironment: Impact on lymphomagenesis. Seminars in Cancer Biology, 2015, 34, 1-2.	9.6	3
146	ACR Appropriateness Criteria® Hodgkin Lymphoma Unfavorable Clinical Stage I and II. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 384-395.	1.3	3
147	R-CHOP Versus R-Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET. Blood, 2020, 136, 39-40.	1.4	3
148	Profiling Genomic Alterations Of Diffuse Large B-Cell Lymphoma (DLBCL) At Diagnosis, Relapse, and Transformation, Using a Novel Clinical Diagnostic Targeted Sequencing Platform. Blood, 2013, 122, 1761-1761.	1.4	3
149	Phase 1 Trial Testing Single Agent CUDC-907, a Novel, Oral Dual Inhibitor of Histone Deacetylase (HDAC) and PI3K: Initial Assessment of Patients with Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL), Including Double Expressor (DE) Lymphoma. Blood, 2015, 126, 257-257.	1.4	3
150	Incidence of Infectious Complications Associated with Bendamustine and Anti-CD20 Monoclonal Antibody Combination at Memorial Sloan Kettering Cancer Center (MSKCC). Blood, 2016, 128, 1778-1778.	1.4	3
151	Antibody-Drug Conjugates in Hematologic Malignancies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e108-e113.	3.8	3
152	Active Surveillance for Newly Diagnosed Nodular Lymphocyte-Predominant Hodgkin Lymphoma. Blood, 2017, 130, 654-654.	1.4	3
153	In vitro and in vivo biologic effects of Interleukin-3 (IL-3) in follicular Low-Grade lymphoma. Leukemia and Lymphoma, 1997, 26, 17-25.	1.3	2
154	Non-Hodgkin Lymphomas: Advanced Diagnostics & Personalized Therapies. , 2013, , .		2
155	New drugs for new targets in lymphoma. Hematological Oncology, 2019, 37, 105-109.	1.7	2
156	A Phase I Study Of An Anti-CD30 x Anti-CD16A Bispecific Tandab Antibody, AFM13, In Patients With Relapsed Or Refractory Hodgkin Lymphoma. Blood, 2013, 122, 5116-5116.	1.4	2
157	Intervention Versus Observation: What Is the Appropriate Endpoint? Assessment of Endpoints in Patients with Advanced Stage Follicular Lymphoma Who Are Initially Observed. Blood, 2016, 128, 1777-1777.	1.4	2
158	The impact of anti-CD20-based therapy on hypogammaglobulinemia in patients with follicular lymphoma. Leukemia and Lymphoma, 2022, , 1-10.	1.3	2
159	Diffuse large B-cell lymphoma: changing treatment paradigms. Oncology, 2014, 28, 339-41.	0.5	2
160	Brentuximab vedotin: the science of common sense. Leukemia and Lymphoma, 2013, 54, 2089-2090.	1.3	1
161	Targeting Programmed Death 1/Programmed Death Ligand 1 in Lymphoma: A Game Changer. Journal of Oncology Practice, 2016, 12, 107-108.	2.5	1
162	Authors' Reply. Journal of Molecular Diagnostics, 2018, 20, 125-126.	2.8	1

#	ARTICLE	IF	CITATIONS
163	Resource Utilization Early after Chimeric Antigen Receptor (CAR) T Cell Infusion for Hematologic Malignancies. Blood, 2018, 132, 616-616.	1.4	1
164	Dual Inhibition of MCL1 and BCL2 in Lymphoma Using Tumor Targeted Nanoparticles. Blood, 2019, 134, 305-305.	1.4	1
165	The Final Report of a Phase I/II Study of Panobinostat in Combination with ICE (Ifosfamide, Carboplatin) Tj ETQq1 1 0.784314 rgBT /O Blood, 2016, 128, 1833-1833.	1.4	1
166	Distinctive Genomic Alterations in Testicular Diffuse Large B Cell Lymphoma. Blood, 2015, 126, 3655-3655.	1.4	1
167	Treatment of Hodgkin lymphoma. , 2016, , 83-93.		1
168	Inhibition of PIM Kinases Targets Synthetic Vulnerabilities and Enhances Antigen Presentation in B-Cell Lymphoma. Blood, 2019, 134, 2858-2858.	1.4	1
169	Recil 2017 Criteria Demonstrated Similar Prognostic Value and Detected a Comparable Treatment Difference between Obinutuzumab- and Rituximab-Chemotherapy Compared with Cheson 2007 and Lugano 2014 Criteria in Patients with Previously Untreated Advanced-Stage Follicular Lymphoma. Blood. 2020. 136. 25-26.	1.4	1
170	Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma. Blood Cancer Journal, 2022, 12, 29.	6.2	1
171	XII. Therapeutic exploitation of autologous Tâ€cell activation in Bâ€cell lymphoma. Hematological Oncology, 2015, 33, 67-69.	1.7	0
172	Clinical applications of genome studies. Hematological Oncology, 2017, 35, 67-69.	1.7	0
173	Will GALEN become more RELEVANT?. Lancet Haematology,the, 2019, 6, e391-e392.	4.6	0
174	Targeting CD30 in Patients with Hodgkin Lymphoma. Hematologic Malignancies, 2015, , 343-354.	0.2	0
175	Defining the Incidence and Clinical Impact of Genomic Alterations Across Different Histologic Types of Lymphoma Using a Clinically Validated Comprehensive Targeted Sequencing Assay. Blood, 2015, 126, 2668-2668.	1.4	0
176	Veliparib (ABT-888), Bendamustine, and Rituximab (VBR) Is Well Tolerated and Efficacious in Patients with Lymphoma: Final Analysis of a Phase 1b Clinical Trial of VB and a Cohort Expansion of Vbr in Patients with B-Cell Lymphoma. Blood, 2015, 126, 2691-2691.	1.4	0
177	Association of MHC-II, PD-L1, and FoxP3 with Disease Status and Outcomes in Patients with Hodgkin Lymphoma. Blood, 2016, 128, 1774-1774.	1.4	0
178	Outcomes of Follicular Lymphoma Patients By Dynamic FLIPI at Diagnosis and Initial Treatment in the Post-Rituximab Era. Blood, 2016, 128, 4119-4119.	1.4	0
179	Dual Inhibition of Histone Deacetylases and Phosphoinositide 3-Kinase Enhances Therapeutic Activity Against B Cell Lymphoma. Blood, 2016, 128, 293-293.	1.4	0
180	MYC-Dependent PI3K and MCL-1 Feedbacks Attenuate BET Inhibitors Activity in Diffuse Large B-Cell Lymphoma. Blood, 2016, 128, 294-294.	1.4	0

#	ARTICLE	IF	CITATIONS
181	Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study. Blood, 2019, 134, 4026-4026.	1.4	0
182	Targeting CD30 in Patients with Hodgkin Lymphoma. Hematologic Malignancies, 2020, , 381-393.	0.2	0
183	Other New Agents for Hodgkin Lymphoma. Hematologic Malignancies, 2020, , 411-416.	0.2	0